Indegene Limited — Investor Meet, 08-10-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Indegene held a corporate update call on October 6, 2025, to discuss its acquisition of BioPharm, a US-based omnichannel marketing business for life sciences. BioPharm reported CY2024 net revenue of $29.2 million and EBITDA of $7.9 million (27% margin). The $104 million acquisition strengthens Indegene's brand activation capabilities, particularly in campaign execution, and expands its HCP data sets to over 3 million. Management sees significant cross-selling opportunities and cost synergies, expecting EPS accretion beyond 5-6 quarters and EBITDA margins to stabilize at 27-28% post-integration. The deal unlocks AI-powered use cases, positioning Indegene as a modern digital sales and marketing partner.